Avidity Biosciences Profit Margin

The latest profit margin for RNA is -1246.35% as of June 2026. That compares with -4247.77% in the prior-year period — up 70.7% year over year. That is below the Healthcare sector average of 13.89%. Investors often review this figure alongside Avidity Biosciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, RNA's profit margin moved from -4247.77% to -1246.35% — a 70.7% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Avidity Biosciences's valuation or profitability profile.

Against Healthcare companies, RNA currently prints -1246.35% for profit margin, while the sector average sits near 13.89%. That is roughly 9071.0% below the sector mean. Large gaps often invite a closer look at Avidity Biosciences's growth, margins, and balance sheet.

Profit Margin shows how effectively Avidity Biosciences converts resources into returns. At -1246.35%, RNA may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -4247.77% in the prior-year period — up 70.7% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting RNA's profit margin (-1246.35%), review year-over-year change from -4247.77%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.